Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use.

Cardiovasc Toxicol

Institute for Sport and Physical Activity Research, Department of Sport and Exercise Science, University of Bedfordshire, Polhill Avenue, Bedford MK41 9EA, UK.

Published: December 2010

The non-therapeutic use of androgenic anabolic steroids (AAS) is associated with sudden cardiac death. Despite this, there is no proposed mechanism by which this may occur. Signal-averaged ECG (SAECG) allows the assessment of cardiac electrical stability, reductions of which are a known risk factor for cardiac arrhythmias. The aim of the present study was to examine cardiac electrical stability using SAECG in a group (n = 15) of long-term AAS users (AAS use 21.3 ± 3.1 years) compared with a group (n = 15) of age-matched weight lifters (WL) and age-matched sedentary controls [C (n = 15)]. AS, WL and C underwent SAECG analysis at rest and following an acute bout of exercise to volitional exhaustion. SAECGs were analyzed using a 40 Hz filter and were averaged over 200 beats. Results indicate a non-significant trend for increased incidence of abnormal SAECG measures at rest in AS (P = 0.55). However, AS demonstrated a significantly higher incidence of abnormalities of SAECG following exercise than C or WL (P < 0.05). In conclusion, the higher incidence of abnormal SAECG measurements immediately post-exercise in the AAS group places them at a greater risk of sudden death. The present study provides a strong contraindication to the use of AAS.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12012-010-9090-yDOI Listing

Publication Analysis

Top Keywords

androgenic anabolic
8
cardiac electrical
8
electrical stability
8
group n = 15
8
cardiac
5
saecg
5
evidence altered
4
altered cardiac
4
cardiac electrophysiology
4
electrophysiology prolonged
4

Similar Publications

Neoadjuvant therapy (NAT) has been studied in clinically localized prostate cancer (PCa) to improve the outcomes from radical prostatectomy (RP) by 'debulking' of high-risk PCa; however, using androgen deprivation therapy (ADT) at this point risks castration resistant PCa (CRPC) clonal proliferation. Our goal is to identify alternative NAT that reduce hormone sensitive PCa (HSPC) without affecting androgen receptor (AR) transcriptional activity. PCa is associated with increased expression and activation of the epidermal growth factor receptor (EGFR) family, including HER2 and ErbB3.

View Article and Find Full Text PDF

Sex-Dependent Efficacy of Sphingosine-1-Phosphate Receptor Agonist FTY720 in Mitigating Huntington's Disease.

Pharmacol Res

December 2024

Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo (UiO) and Section of Neuropathology Research, Department of Pathology, Clinics for Laboratory Medicine (KLM), Oslo University Hospital (OUS), Sognsvannsveien 20, N-0372 Oslo, Norway; Institute of Nutritional Medicine (INUM) and Lübeck Institute of Dermatology (LIED), University of Lübeck (UzL) and University Medical Center Schleswig-Holstein (UKSH), Ratzeburger Allee 160, D-23538 Lübeck, Germany; Faculty of Medicine and Life Sciences, University of Latvia, Jelgavas iela 3, LV-1004 Rīga, Latvia; School of Neurobiology, Biochemistry and Biophysics, The Georg S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, IL-6997801, Israel. Electronic address:

Huntington's disease (HD) is a debilitating neurodegenerative disorder characterized by severe motor deficits, cognitive decline and psychiatric disturbances. An early and significant morphological hallmark of HD is the activation of astrocytes triggered by mutant huntingtin, leading to the release of inflammatory mediators. Fingolimod (FTY), an FDA-approved sphingosine-1-phosphate (S1P) receptor agonist is used to treat multiple sclerosis (MS), a neuroinflammatory disease, and has shown therapeutic promise in other neurological conditions.

View Article and Find Full Text PDF

Aim: to evaluate the efficacy of an integrated management approach for ovarian endometriomas using Dienogest administered both before and after laparoscopic cyst enucleation in women with infertility.

Materials And Methods: The prospective, comparative clinical trial included 44 patients aged 18-35 years with ovarian endometriomas and infertility. Patients were randomly divided into two groups: the study group (20 participants) received Dienogest for six months before and after laparoscopic cyst enucleation, while the control group (24 participants) underwent laparoscopic cyst enucleation without additional hormonal treatment.

View Article and Find Full Text PDF

Introduction: Endometrial cyst, or endometrioma, is a specific form of endometriosis that often reveals with severe symptoms and requires ongoing treatment. High rate of recurrence after surgical intervention presents a significant challenge in the management of this disease.

Aim Of The Study: Aim of the study was to determine the effectiveness of combined therapy (surgical and hormonal) of endometrioma in terms of development of recurrences, the rate of pregnancy and change in pain intensity.

View Article and Find Full Text PDF

Background: Insulin resistance (IR) is closely correlated with a deficiency or decrease of testosterone levels in males. Cardiometabolic index (CMI) is correlated with various diseases correlated with IR. The primary objective of this study is to explore the correlation between CMI and testosterone levels in male adults.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!